Table 1:
Laboratory Values at Time of Hepatitis Presentation
| Laboratory Values At Time of Presentation | ||||
|---|---|---|---|---|
| Laboratory Test | Patient A | Patient B | Patient C | Patient D |
| ALT (10–35 U/L) | 2,445 | 2,763 | 2,763 | 2,502 |
| AST (15–40 U/L) | 3,134 | 2,287 | 2,789 | 3,485 |
| Total Bilirubin (0.2–1.2 mg/dL) | 10.7 | 7.4 | 6.7 | 7.5 |
| Direct Bilirubin (0–0.3 mg/dL) | 6.1 | 5.9 | 2.6 | 6.6 |
| GGT (11–21 U/L) | 163 | 64 | 178 | 146 |
| INR (<1.5) | 1.49 | 1.2 | 0.98 | 1.05 |
| WBC (5.7–10.5 × 103/μL) | 3.54 | 3.00 | 2.53 | 4.38 |
| ALC (1.23–2.69 × 103/μL) | 1.43 | 0.97 | 0.56 | 1.31 |
| ANC (1.8–5.4 × 103/μL) | 1.48 | 0.97 | 1.2 | 2.33 |
| Platelets (150–500 × 103/μL) | 86 | 154 | 182 | 26 |
| Hemoglobin (11.1–14.5 g/μL) | 13.6 | 15 | 11.1 | 13.6 |
| Reticulocyte Count (0.8–2.2%) | 3.7 | |||
| Ferritin (10–60 ng/mL) | 792 | 522 | 456 | |
| Fibrinogen (150–400 MGS/dL) | 140 | 185 | 177 | |
| Triglycerides (<75 mg/dL) | 213 | 279 | 316 | |
| Soluble IL-2 R (45–1,105 unit/mL) | 7,987 | 13,310 | 20,600 | |
| NK Cell Function (50:1) (≥20%) | 2 | 1 | 3 | |
| NK Cell Function (25:1) (≥10%) | 2 | 1 | 2 | |
| NK Cell Function (12:1) (≥5%) | 1 | 0 | 1 | |
| NK Cell Function (6:1) (≥1%) | 1 | |||
| NK Cell Lytic Units (≥2.6%) | 0 | 0 | 0 | |
| NK Cell CD16/56% (4–26%) | 2 | 4 | 1 | |
| Perforin: | ||||
| Positive of NK (73–91%) | 76 | 95 | ||
| Intensity (98–181 MCF) | 112 | 166 | ||
| Positive of CD8 (0–16%) | 28 | 27 | ||
| Positive of NKT (0–28%) | NR | |||
| Granzyme B: | ||||
| Positive of NK (80–98%) | 92 | 98 | ||
| Intensity (152–825 MCF) | 539 | 1,661 | ||
| Positive of CD8 (0–61%) | 88 | 87 | ||
| Positive of NKT (0–72%) | NR | |||
| CD56 Bright Positive (1.7–13.4%) | 1.3 | 9.3 | ||
| Surface Marker (SM) T&B Panel: | ||||
| WBC Total (4,000–12,000/μL) | 5,810 | 730 | 10,000 | 3,980 |
| Lymph Abs (1,000–5,500/μL) | 471 | 530 | 130 | 530 |
| CD16/CD56 NK Cells (4–17%) | 2 | <1 | 4 | 1 |
| CD16/CD56 Abs (100–480/μL) | 8 | <5 | 6 | 7 |
| CD19 (B4) SM (13–27%) | 30 | 5 | 12 | 10 |
| CD19 SM Abs (270–860/μL) | 142 | 27 | 16 | 53 |
| CD3 (T3) SM (60–76%) | 68 | 94 | 83 | 88 |
| CD3 SM Abs (1,200–2,600/μL) | 322 | 498 | 108 | 468 |
| CD4 (T4) SM (31–47%) | 5 | 11 | 19 | 8 |
| T4 SM Abs (650–1,500/μL) | 21 | 57 | 25 | 43 |
| CD8 (T8) SM (18–35%) | 53 | 81 | 55 | 77 |
| T8 SM Abs (370–1,100/μL) | 248 | 429 | 71 | 409 |
| CD4/CD8 SM (0.98–3.24) | 0.09 | 0.13 | 0.35 | 0.11 |